# Haemonetics Corp: financial statements, quarterly

HAE · NYSE · CIK 313143 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 3

Pages: [Overview](/companies/hae.md) · [Financials](/companies/hae/financials.md) · [Filings](/companies/hae/filings.md) · [Insiders](/companies/hae/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hae/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-30) | Q4 FY2024 (2024-03-30) | Q1 FY2025 (2024-06-29) | Q2 FY2025 (2024-09-28) | Q3 FY2025 (2024-12-28) | Q4 FY2025 (2025-03-29) | Q1 FY2026 (2025-06-28) | Q2 FY2026 (2025-09-27) | Q3 FY2026 (2025-12-27) | Q4 FY2026 (2026-03-28) | Q1 FY2027 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [318](/filings/0000313143-24-000063.md) | [336](/filings/0000313143-25-000012.md) | [343 d](/filings/0000313143-26-000050.md) | [336](/filings/0000313143-25-000058.md) | [346](/filings/0000313143-25-000075.md) | [349](/filings/0000313143-26-000010.md) | [331 d](/filings/0000313143-26-000050.md) | [321](/filings/0000313143-26-000120.md) | [327](/filings/0000313143-25-000075.md) | [339](/filings/0000313143-26-000010.md) | [346 d](/filings/0000313143-26-000050.md) | [339](/filings/0000313143-26-000120.md) |
| Cost of revenue | $m | [148](/filings/0000313143-24-000063.md) | [158](/filings/0000313143-25-000012.md) | [167 d](/filings/0000313143-26-000050.md) | [161](/filings/0000313143-25-000058.md) | [158](/filings/0000313143-25-000075.md) | [155](/filings/0000313143-26-000010.md) | [138 d](/filings/0000313143-26-000050.md) | [129](/filings/0000313143-26-000120.md) | [133](/filings/0000313143-25-000075.md) | [137](/filings/0000313143-26-000010.md) | [148 d](/filings/0000313143-26-000050.md) | [137](/filings/0000313143-26-000120.md) |
| Gross profit | $m | [171](/filings/0000313143-24-000063.md) | [178](/filings/0000313143-25-000012.md) | [176 d](/filings/0000313143-26-000050.md) | [175](/filings/0000313143-25-000058.md) | [187](/filings/0000313143-25-000075.md) | [194](/filings/0000313143-26-000010.md) | [193 d](/filings/0000313143-26-000050.md) | [192](/filings/0000313143-26-000120.md) | [195](/filings/0000313143-25-000075.md) | [202](/filings/0000313143-26-000010.md) | [198 d](/filings/0000313143-26-000050.md) | [203](/filings/0000313143-26-000120.md) |
| Research and development | $m | [12.7](/filings/0000313143-24-000063.md) | [13.3](/filings/0000313143-25-000012.md) | [15.9 d](/filings/0000313143-26-000050.md) | [14.4](/filings/0000313143-25-000058.md) | [14.1](/filings/0000313143-25-000075.md) | [15.8](/filings/0000313143-26-000010.md) | [18.3 d](/filings/0000313143-26-000050.md) | [16.3](/filings/0000313143-26-000120.md) | [14.9](/filings/0000313143-25-000075.md) | [14.2](/filings/0000313143-26-000010.md) | [14.4 d](/filings/0000313143-26-000050.md) | [16.2](/filings/0000313143-26-000120.md) |
| Selling, general and administrative | $m | [115](/filings/0000313143-24-000063.md) | [112](/filings/0000313143-25-000012.md) | [109 d](/filings/0000313143-26-000050.md) | [108](/filings/0000313143-25-000058.md) | [107](/filings/0000313143-25-000075.md) | [106](/filings/0000313143-26-000010.md) | [115 d](/filings/0000313143-26-000050.md) | [111](/filings/0000313143-26-000120.md) | [102](/filings/0000313143-25-000075.md) | [109](/filings/0000313143-26-000010.md) | [121 d](/filings/0000313143-26-000050.md) | [119](/filings/0000313143-26-000120.md) |
| Operating income | $m | [35.3](/filings/0000313143-24-000063.md) | [46.0](/filings/0000313143-25-000012.md) | [29.9 d](/filings/0000313143-26-000050.md) | [39.8](/filings/0000313143-25-000058.md) | [51.7](/filings/0000313143-25-000075.md) | [59.0](/filings/0000313143-26-000010.md) | [71.3 d](/filings/0000313143-26-000050.md) | [53.9](/filings/0000313143-26-000120.md) | [58.5](/filings/0000313143-25-000075.md) | [67.4](/filings/0000313143-26-000010.md) | [(23.0) d](/filings/0000313143-26-000050.md) | [57.5](/filings/0000313143-26-000120.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [7.9](/filings/0000313143-24-000063.md) | [12.8](/filings/0000313143-25-000012.md) | [3.0 d](/filings/0000313143-26-000050.md) | [8.3](/filings/0000313143-25-000058.md) | [10.9](/filings/0000313143-25-000075.md) | [12.4](/filings/0000313143-26-000010.md) | [12.8 d](/filings/0000313143-26-000050.md) | [11.1](/filings/0000313143-26-000120.md) | [12.6](/filings/0000313143-25-000075.md) | [15.2](/filings/0000313143-26-000010.md) | [(8.3) d](/filings/0000313143-26-000050.md) | [14.6](/filings/0000313143-26-000120.md) |
| Net income | $m | [24.9](/filings/0000313143-25-000012.md) | [31.2](/filings/0000313143-25-000012.md) | [20.4 d](/filings/0000313143-26-000050.md) | [38.4](/filings/0000313143-26-000010.md) | [33.8](/filings/0000313143-26-000010.md) | [37.5](/filings/0000313143-26-000010.md) | [58.0 d](/filings/0000313143-26-000050.md) | [34.0](/filings/0000313143-26-000120.md) | [38.7](/filings/0000313143-26-000010.md) | [44.7](/filings/0000313143-26-000010.md) | [(20.1) d](/filings/0000313143-26-000050.md) | [33.0](/filings/0000313143-26-000120.md) |
| Diluted EPS | $ per share | [0.48](/filings/0000313143-24-000063.md) | [0.61](/filings/0000313143-25-000012.md) | not reported | [0.74](/filings/0000313143-25-000058.md) | [0.66](/filings/0000313143-25-000075.md) | [0.74](/filings/0000313143-26-000010.md) | not reported | [0.70](/filings/0000313143-26-000120.md) | [0.81](/filings/0000313143-25-000075.md) | [0.95](/filings/0000313143-26-000010.md) | not reported | [0.72](/filings/0000313143-26-000120.md) |
| Basic EPS | $ per share | [0.49](/filings/0000313143-24-000063.md) | [0.62](/filings/0000313143-25-000012.md) | not reported | [0.75](/filings/0000313143-25-000058.md) | [0.66](/filings/0000313143-25-000075.md) | [0.75](/filings/0000313143-26-000010.md) | not reported | [0.71](/filings/0000313143-26-000120.md) | [0.81](/filings/0000313143-25-000075.md) | [0.96](/filings/0000313143-26-000010.md) | not reported | [0.73](/filings/0000313143-26-000120.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-30) | FY2024 (2024-03-30) | Q1 FY2025 (2024-06-29) | Q2 FY2025 (2024-09-28) | Q3 FY2025 (2024-12-28) | FY2025 (2025-03-29) | Q1 FY2026 (2025-06-28) | Q2 FY2026 (2025-09-27) | Q3 FY2026 (2025-12-27) | FY2026 (2026-03-28) | Q1 FY2027 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [351](/filings/0000313143-23-000057.md) | [194](/filings/0000313143-24-000007.md) | [179](/filings/0000313143-25-000025.md) | [344](/filings/0000313143-24-000054.md) | [299](/filings/0000313143-24-000063.md) | [321](/filings/0000313143-25-000012.md) | [307](/filings/0000313143-26-000050.md) | [293](/filings/0000313143-25-000058.md) | [296](/filings/0000313143-25-000075.md) | [363](/filings/0000313143-26-000010.md) | [245](/filings/0000313143-26-000120.md) | [223](/filings/0000313143-26-000120.md) |
| Current assets | $m | [866](/filings/0000313143-23-000057.md) | [765](/filings/0000313143-24-000007.md) | [769](/filings/0000313143-25-000025.md) | [979](/filings/0000313143-24-000054.md) | [956](/filings/0000313143-24-000063.md) | [1,006](/filings/0000313143-25-000012.md) | [935](/filings/0000313143-26-000050.md) | [913](/filings/0000313143-25-000058.md) | [900](/filings/0000313143-25-000075.md) | [944](/filings/0000313143-26-000010.md) | [835](/filings/0000313143-26-000120.md) | [811](/filings/0000313143-26-000120.md) |
| Total assets | $m | [2,011](/filings/0000313143-23-000057.md) | [2,200](/filings/0000313143-24-000007.md) | [2,196](/filings/0000313143-25-000025.md) | [2,541](/filings/0000313143-24-000054.md) | [2,525](/filings/0000313143-24-000063.md) | [2,531](/filings/0000313143-25-000012.md) | [2,451](/filings/0000313143-26-000050.md) | [2,462](/filings/0000313143-25-000058.md) | [2,442](/filings/0000313143-25-000075.md) | [2,491](/filings/0000313143-26-000010.md) | [2,396](/filings/0000313143-26-000120.md) | [2,365](/filings/0000313143-26-000120.md) |
| Current liabilities | $m | [264](/filings/0000313143-23-000057.md) | [262](/filings/0000313143-24-000007.md) | [300](/filings/0000313143-25-000025.md) | [260](/filings/0000313143-24-000054.md) | [274](/filings/0000313143-24-000063.md) | [253](/filings/0000313143-25-000012.md) | [578](/filings/0000313143-26-000050.md) | [531](/filings/0000313143-25-000058.md) | [548](/filings/0000313143-25-000075.md) | [540](/filings/0000313143-26-000010.md) | [283](/filings/0000313143-26-000120.md) | [263](/filings/0000313143-26-000120.md) |
| Long-term debt | $m | [749](/filings/0000313143-23-000057.md) | [857](/filings/0000313143-24-000007.md) | [798](/filings/0000313143-25-000025.md) | [1,218](/filings/0000313143-24-000054.md) | [1,220](/filings/0000313143-24-000063.md) | [1,220](/filings/0000313143-25-000012.md) | [921](/filings/0000313143-26-000050.md) | [921](/filings/0000313143-25-000058.md) | [920](/filings/0000313143-25-000075.md) | [920](/filings/0000313143-26-000010.md) | [1,220](/filings/0000313143-26-000120.md) | [1,169](/filings/0000313143-26-000120.md) |
| Current portion of debt | $m | [13.6](/filings/0000313143-23-000057.md) | [13.7](/filings/0000313143-24-000007.md) | [10.2](/filings/0000313143-25-000025.md) | [5.1](/filings/0000313143-24-000054.md) | [5.4](/filings/0000313143-24-000063.md) | [5.1](/filings/0000313143-25-000012.md) | [304](/filings/0000313143-26-000050.md) | [304](/filings/0000313143-25-000058.md) | [304](/filings/0000313143-25-000075.md) | [305](/filings/0000313143-26-000010.md) | [5.0](/filings/0000313143-26-000120.md) | [5.0](/filings/0000313143-26-000120.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [894](/filings/0000313143-25-000012.md) | [943](/filings/0000313143-25-000012.md) | [960](/filings/0000313143-26-000050.md) | [905](/filings/0000313143-26-000010.md) | [879](/filings/0000313143-26-000010.md) | [907](/filings/0000313143-26-000010.md) | [821](/filings/0000313143-26-000120.md) | [882](/filings/0000313143-26-000120.md) | [849](/filings/0000313143-26-000010.md) | [911](/filings/0000313143-26-000010.md) | [796](/filings/0000313143-26-000120.md) | [837](/filings/0000313143-26-000120.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-30) | Q4 FY2024 (2024-03-30) | Q1 FY2025 (2024-06-29) | Q2 FY2025 (2024-09-28) | Q3 FY2025 (2024-12-28) | Q4 FY2025 (2025-03-29) | Q1 FY2026 (2025-06-28) | Q2 FY2026 (2025-09-27) | Q3 FY2026 (2025-12-27) | Q4 FY2026 (2026-03-28) | Q1 FY2027 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [99.1 d](/filings/0000313143-24-000063.md) | [(0.5) d](/filings/0000313143-25-000012.md) | [64.1 d](/filings/0000313143-26-000050.md) | [(27.4)](/filings/0000313143-25-000058.md) | [48.8 d](/filings/0000313143-25-000075.md) | [43.8 d](/filings/0000313143-26-000010.md) | [117 d](/filings/0000313143-26-000050.md) | [17.4](/filings/0000313143-26-000120.md) | [111 d](/filings/0000313143-25-000075.md) | [93.6 d](/filings/0000313143-26-000010.md) | [70.9 d](/filings/0000313143-26-000050.md) | [52.3](/filings/0000313143-26-000120.md) |
| Capital expenditure | $m | [9.1 d](/filings/0000313143-24-000063.md) | [14.6 d](/filings/0000313143-25-000012.md) | [6.7 d](/filings/0000313143-26-000050.md) | [5.7](/filings/0000313143-25-000058.md) | [9.4 d](/filings/0000313143-25-000075.md) | [8.5 d](/filings/0000313143-26-000010.md) | [15.6 d](/filings/0000313143-26-000050.md) | [3.8](/filings/0000313143-26-000120.md) | [5.0 d](/filings/0000313143-25-000075.md) | [6.3 d](/filings/0000313143-26-000010.md) | [17.7 d](/filings/0000313143-26-000050.md) | [7.9](/filings/0000313143-26-000120.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0000313143-25-000012.md) | [0.0 d](/filings/0000313143-26-000050.md) | not reported | not reported | [0.0 d](/filings/0000313143-26-000010.md) | [150 d](/filings/0000313143-26-000050.md) | not reported | not reported | [0.0 d](/filings/0000313143-26-000010.md) | [100 d](/filings/0000313143-26-000050.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-01) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-07-01) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-30) | Q1 FY2025 (2024-06-29) | Q2 FY2025 (2024-09-28) | Q3 FY2025 (2024-12-28) | Q1 FY2026 (2025-06-28) | Q2 FY2026 (2025-09-27) | Q3 FY2026 (2025-12-27) | Q1 FY2027 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [51.6](/filings/0000313143-23-000057.md) | [51.2](/filings/0000313143-24-000007.md) | [51.3](/filings/0000313143-24-000054.md) | [51.4](/filings/0000313143-24-000063.md) | [51.4](/filings/0000313143-25-000012.md) | [51.6](/filings/0000313143-25-000058.md) | [51.2](/filings/0000313143-25-000075.md) | [50.6](/filings/0000313143-26-000010.md) | [48.4](/filings/0000313143-26-000120.md) | [47.7](/filings/0000313143-25-000075.md) | [47.0](/filings/0000313143-26-000010.md) | [45.7](/filings/0000313143-26-000120.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,497,051 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0000313143-26-000120.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.